ResMed
manufacturer of CPAP masks, machines and products that diagnose, treat or help manage respiratory conditions
RMD NYSE · home listing
RMD Australian Securities Exchange
ISIN US7611521078 SEC CIK 943819
Follow ResMed
Weekly email: filings, results
Revenue, last quarter
$1.4B
+5.9% vs same quarter last year
Net income
$418.4M
+20% vs same quarter last year
EPS, diluted
$2.92
+23.2% vs same quarter last year
Operating cash flow
$422.4M
−7.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $5.7B | $1.5B |
| FY25 | $5.1B | $1.4B |
| FY24 | $4.7B | $1B |
| FY23 | $4.2B | $898M |
| FY22 | $3.6B | $779M |
| FY21 | $3.2B | $474.5M |
| FY20 | $3B | $621.7M |
| FY19 | $2.6B | $404.6M |
| FY18 | $2.3B | $315.6M |
| FY17 | $2.1B | $342.3M |
| FY16 | $1.8B | $352.4M |
| FY15 | $1.7B | $352.9M |
| FY14 | $1.6B | $345.3M |
| FY13 | $1.5B | $307.1M |
| FY12 | $1.4B | $254.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | 61.1% | 33.4% | 26.9% |
| FY25 | 59.4% | 32.7% | 27.2% |
| FY24 | 56.7% | 28.2% | 21.8% |
| FY23 | 55.8% | 26.8% | 21.3% |
| FY22 | 56.6% | 28% | 21.8% |
| FY21 | 57.5% | 28.3% | 14.8% |
| FY20 | 58.1% | 27.4% | 21% |
| FY19 | 57.3% | 22.2% | 15.5% |
| FY18 | 57% | 23.2% | 13.5% |
| FY17 | 58.1% | 20.6% | 16.6% |
| FY16 | 58% | 23.3% | 19.2% |
| FY15 | 60.2% | 24.4% | 21% |
| FY14 | 63.7% | 26.1% | 22.2% |
| FY13 | 62.1% | 23.4% | 20.3% |
| FY12 | 60% | 21.5% | 18.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | $1.6B |
| FY25 | $1.7B |
| FY24 | $1.3B |
| FY23 | $573.6M |
| FY22 | $216.3M |
| FY21 | $634M |
| FY20 | $706.9M |
| FY19 | $390.3M |
| FY18 | $442.4M |
| FY17 | $351.8M |
| FY16 | $489.4M |
| FY15 | $320.7M |
| FY14 | $318.5M |
| FY13 | $339.2M |
| FY12 | $336M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY26 | $349.7M | $700M |
| FY25 | $310.9M | $300M |
| FY24 | $282.3M | $150M |
| FY23 | $258.3M | $0 |
| FY22 | $245.3M | $0 |
| FY21 | $226.7M | - |
| FY20 | $225.1M | - |
| FY19 | $211.7M | $22.8M |
| FY18 | $199.5M | $53.8M |
| FY17 | $186.3M | - |
| FY16 | $168.1M | $102.1M |
| FY15 | $157.3M | $160.3M |
| FY14 | $141.5M | $202.2M |
| FY13 | $97.2M | $186.3M |
| FY12 | - | $392.7M |
- ResMed
- Healthcare median
Show the numbers
| Year | ResMed | Healthcare median |
|---|---|---|
| FY26 | 26.9% | −11.1% |
| FY25 | 27.2% | −30.6% |
| FY24 | 21.8% | −47% |
| FY23 | 21.3% | −58% |
| FY22 | 21.8% | −80.4% |
| FY21 | 14.8% | −71.9% |
| FY20 | 21% | −62.2% |
| FY19 | 15.5% | −46.3% |
| FY18 | 13.5% | −49.6% |
| FY17 | 16.6% | −45.9% |
| FY16 | 19.2% | −36% |
| FY15 | 21% | −38.4% |
| FY14 | 22.2% | −35.5% |
| FY13 | 20.3% | −37.1% |
| FY12 | 18.6% | −29.1% |